Genetic, ethnic, and gender differences in the pharmacokinetics of antiretroviral agents.

Genetic, ethnic, and gender differences in the pharmacokinetics of antiretroviral agents.

Item
http://www.wikidata.org/entity/Q36592753
Interindividual variability in pharmacokinetics of generic nucleoside reverse transcriptase inhibitors in TB/HIV-coinfected Ghanaian patients: UGT2B7*1c is associated with faster zidovudine clearance and glucuronidationGender difference in 2-year mortality and immunological response to ART in an HIV-infected Chinese population, 2006-2008Pharmacogenetic-based efavirenz dose modification: suggestions for an African population and the different CYP2B6 genotypesSex differences in atazanavir pharmacokinetics and associations with time to clinical events: AIDS Clinical Trials Group Study A5202.Polymorphic variants of cytochrome P450 2B6 (CYP2B6.4-CYP2B6.9) exhibit altered rates of metabolism for bupropion and efavirenz: a charge-reversal mutation in the K139E variant (CYP2B6.8) impairs formation of a functional cytochrome p450-reductase cPopulation pharmacokinetic/pharmacogenetic model for optimization of efavirenz therapy in Caucasian HIV-infected patients.Population pharmacokinetic analysis and pharmacogenetics of raltegravir in HIV-positive and healthy individualsDialogues on diversifying clinical trials: successful strategies for engaging women and minorities in clinical trials.Superior Effects of Antiretroviral Treatment among Men Who have Sex with Men Compared to Other HIV At-Risk Populations in a Large Cohort Study in Hunan, ChinaADME pathway approach for pharmacogenetic studies of anti-HIV therapy.Polymorphic CYP2B6: molecular mechanisms and emerging clinical significance.Body weight cutoff for daily dosage of efavirenz and 60-week efficacy of efavirenz-based regimen in human immunodeficiency virus and tuberculosis coinfected patients receiving rifampin.CYP2B6 genotype-based efavirenz dose recommendations during rifampicin-based antituberculosis cotreatment for a sub-Saharan Africa population.Efavirenz and Metabolites in Cerebrospinal Fluid: Relationship with CYP2B6 c.516G→T Genotype and Perturbed Blood-Brain Barrier Due to Tuberculous Meningitis.Long-Term Effect of Rifampicin-Based Anti-TB Regimen Coadministration on the Pharmacokinetic Parameters of Efavirenz and 8-Hydroxy-Efavirenz in Ethiopian Patients.Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Relationships of Etravirine in HIV-1-Infected, Treatment-Experienced Children and Adolescents in PIANO.Pharmacogenetics-based population pharmacokinetic analysis of efavirenz in HIV-1-infected individuals.
P2860

Genetic, ethnic, and gender differences in the pharmacokinetics of antiretroviral agents.

Item
http://www.wikidata.org/entity/Q36592753
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Genetic, ethnic, and gender differences in the pharmacokinetics of antiretroviral agents.
@ast
Genetic, ethnic, and gender differences in the pharmacokinetics of antiretroviral agents.
@en
type
label
Genetic, ethnic, and gender differences in the pharmacokinetics of antiretroviral agents.
@ast
Genetic, ethnic, and gender differences in the pharmacokinetics of antiretroviral agents.
@en
prefLabel
Genetic, ethnic, and gender differences in the pharmacokinetics of antiretroviral agents.
@ast
Genetic, ethnic, and gender differences in the pharmacokinetics of antiretroviral agents.
@en
P1433
P1476
P2093
P2860
P2888
P304
P31
P356
P433
P478
P50
P577
P698
P921
P356
P1433
P1476
Genetic, ethnic, and gender differences in the pharmacokinetics of antiretroviral agents.
@en
P2093
P2860
P2888
P304
P31
P356
P433
P478
P50
P577
P698
P921